Skip to main content

Table 2 Association between baseline autoantibody status and radiological destruction

From: Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis

  RF+ (n= 162) vs RF- (n= 94) Anti-CCP + (n= 148) vs anti-CCP- (n= 108) Anti-MCV+ (n= 180) vs anti-MCV- (n= 74) Anti-CII + (> 200 AU/mL; n= 8) versus anti-CII- (n= 248)
Larsen score baseline 4.000 versus 5.000, P = NS (0.13) 4.000 versus 5.000, P = NS (0.16) 4.375 versus 5.000, P = NS (0.21) 13.750 versus 4.375, P = 0.0486*
Larsen score 1 year 10,500 versus10.500, P = NS (0.65) 10.500 versus 10,750, P = NS (0.66) 11.000 versus 10.000, P = NS (0.99) 21.500 versus 10.500, P = NS (0.0799)
Larsen score 2 years 14.000 versus 13.250, P = NS (0.69) 14.000 versus 13.000, P = NS (0.57) 14.375 versus 10,250, P = NS (0.24) 24.000 versus 13.500, P = NS (0.19)
ΔLarsen score 1 yr -baseline 4.500 versus 4.250, P = NS (0.32) 4.500 versus 4.250, P = NS (0.29) 4.500 versus 3.750, P = NS (0.19) 7.375 versus 4.250, P = NS (0.27)
ΔLarsen score 2 yrs -baseline 7.250 versus 6.250, P = 0.0354* 7.500 versus 6.250
P = 0.0102*
7.750 versus 5.250, P = 0.0028* 9.250 versus 6.500, P = NS (0.50)
ΔLarsen score 2 yrs -1 yr 2.500 versus 1.250, P = 0.0009* 2.750 versus 1.000, p < 0.0001* 2.750 versus 1.000, p < 0.0001* 3.000 versus 2,.250, P = NS (0.48)
  1. Differences in median Larsen score between patients with and without different autoantibodies and changes in median Larsen score are given for 256 patients with early rheumatoid arthritis. Anti-MCV data were missing for two patients. ΔLarsen score, difference in Larsen score; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; Anti-MCV, antibodies against modified citrullinated vimentin; Anti-CII, anti-native human collagen type II. *P < 0.05.